ESR1 and breast cancer: While the mechanistic underpinnings for higher selectivity of BET inhibitors toward the Y537S mutant breast cancer cells remain to be elucidated, Jeselsohn and coworkers have previously shown that Y537S mutation activates unique transcriptional programs relative to other ESR1 mutations (and WT cells stimulated with β-estradiol) (11).